CompletedNCT00937040
OROS methylphenidate for adults with ADHD
About this title
Read the official source —Medication studyAges 18–65
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJuly 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 357
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00937040
- Official title
Show the full official title
A Placebo Controlled Double-Blind, Parallel Group, Individualizing Dosing Study Optimizing Treatment of Adults With Attention Deficit Hyperactivity Disorder to an Effective Response With OROS Methylphenidate
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
Who is behind this study?
The study sponsor is Ortho-McNeil Janssen Scientific Affairs, LLC.
Did this study involve medication?
Yes. The study involved medication, including OROS MPH, Placebo, OROS MPH Tablets and Placebo Tablets.
Who was this study for?
Listed age limits: 18 years to 65 years.
